Holdings of Lion Point Capital, LP
27 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 59.6 % of the equity sleeve
Sector breakdown
- Materials 3.2 %
- Unattributed 96.8 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- US 96.3 %
- GB 3.7 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | US | 26 | 11.4M $ | 96.27 % |
| 2 | GB | 1 | 442.4K $ | 3.73 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Praxis Precision Medicines Inc | 4,450 | 1.4M $ | |
| 2 | Geron Corp | 578,000 | 861.2K $ | |
| 3 | Syndax Pharmaceuticals Inc | 36,000 | 841K $ | |
| 4 | Ardelyx Inc | 128,650 | 770.6K $ | |
| 5 | Benitec Biopharma Inc | 62,000 | 660.3K $ | |
| 6 | Sarepta Therapeutics Inc | 28,500 | 620.2K $ | |
| 7 | Disc Medicine Inc | 8,100 | 517.9K $ | |
| 8 | CUE BIOPHARMA INC | 2,202,854 | 506.4K $ | |
| 9 | Compass Pathways plc | 80,000 | 442.4K $ | |
| 10 | Lantheus Holdings Inc | 5,500 | 417.2K $ | |
| 11 | JASPER THERAPEUTICS INC | 465,000 | 407.4K $ | |
| 12 | Humacyte Inc | 650,000 | 394.4K $ | |
| 13 | Viatris Inc | 27,700 | 374.2K $ | |
| 14 | Kura Oncology Inc | 46,000 | 374K $ | |
| 15 | Bridgebio Pharma Inc | 5,000 | 371.3K $ | |
| 16 | Dyne Therapeutics Inc | 18,000 | 326.3K $ | |
| 17 | Rocket Pharmaceuticals Inc | 86,000 | 307.9K $ | |
| 18 | Pacira BioSciences Inc | 13,500 | 305.1K $ | |
| 19 | Edgewise Therapeutics Inc | 9,100 | 286.7K $ | |
| 20 | Mineralys Therapeutics Inc | 10,500 | 284.4K $ | |
| 21 | Seres Therapeutics Inc | 31,570 | 280K $ | |
| 22 | Janux Therapeutics Inc | 19,000 | 264.1K $ | |
| 23 | REGENXBIO Inc | 26,600 | 222.9K $ | |
| 24 | Azenta Inc | 9,700 | 205K $ | |
| 25 | Innoviva Inc | 8,200 | 191.1K $ | |
| 26 | Arcutis Biotherapeutics Inc | 5,250 | 123.7K $ | |
| 27 | SPRUCE BIOSCIENCES INC | 1,000 | 65.4K $ |